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Histone deacetylase inhibitors, such as phenylbutyrate, are
currently undergoing clinical trials as potential anticancer
agents. Phenylbutyrate can induce cell differentiation and
apoptosis in a number of cancer cell types and can act in
synergy with ionizing radiation and chemotherapy to induce
apoptosis. We used the sea urchin embryo basement mem-
brane invasion assay to show that phenylbutyrate potently
inhibited the invasive properties of both prostate and breast
cancer cells at clinically achievable doses. This inhibition was
dose-dependent and persisted for at least 24 hr after the drug
was removed. These results suggest that in addition to acti-
vating apoptosis in cancer cells, phenylbutyrate may be used
in prevention of metastatic disease.
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A number of clinical trials are currently ongoing to evaluate the
efficacy of histone deacetylase (HDAC) inhibitors in the treatment
of cancer.1,2 Phenylbutyrate is an HDAC inhibitor that is odorless
and orally active and has shown promising results in Phase I and
Phase II clinical trials.1 As an HDAC inhibitor, phenylbutyrate
induces hyperacetylation of chromatin leading to changes in gene
expression2,3 and the induction of differentiation and apoptosis.4–7
It has been shown that butyrate and phenylbutyrate can act in
synergy with radiation8–11 or chemotherapy11,12 to induce cells to
undergo apoptosis. Furthermore, some HDAC inhibitors have re-
cently been found to inhibit angiogenesis.13 The anti-angiogenic
properties of HDAC inhibitors may occur through the down reg-
ulation of VEGF expression.10
In our previous study we found that phenylbutyrate reduced the
expression of caveolin-1.10 Although the exact role of caveolin-1
in carcinogenesis is unclear, caveolin-1 is thought to regulate
integrin signaling14 and high expression of caveolin-1 is associated
with a metastatic phenotype in breast and prostate cancer.15–17 In
addition to reducing caveolin-1 expression, phenylbutyrate has
been found to reduce the expression of the invasion-related plas-
minogen activator, urokinase, in glioma cells18 and reduce the
invasiveness of cancer cells in artificial matrigel chamber invasion
assays.18,19
We explored the ability of phenylbutyrate to block the invasiveness
of metastatic prostate and breast cancer cells using the sea urchin
embryo basement membrane invasion assay. This invasion assay
utilizes the natural occurring, selectively permeable basement mem-
branes of sea urchin embryos (SU-ECM) as invasion substrates.20,21
The sea urchin embryo basement membrane is functionally analogous
to the mammalian basement membranes underlying the epidermis
because it is invaded by pigment cells during development.22 We have
shown previously that these SU-ECM invasion substrates can be
selectively invaded by metastatic tumor cells.20 In fact, we have
shown that this assay can predict the metastatic potential of cancer cell
lines with greater than 99% confidence.20 We show that phenylbu-
tyrate effectively inhibits the invasiveness of metastatic prostate and
breast cancer cells in the SU-ECM invasion assay.
MATERIAL AND METHODS
Cell cultures and phenylbutyrate treatments
PC3 and DU-145 cells were obtained from American Type Culture
Collection (Manassas, VA) and Steve Ethier, University of Michigan,
kindly provided us with the SUM-149 cell line. The PC3 and DU-145
cells were cultured in MEM (Life Technologies, Grand Island, NY)
supplemented with 10% FBS (HyClone, Logan, UT), with 1 amino
acids, vitamins and antibiotics. SUM-149 cells were grown in Ham’s
F-12 media supplemented with 5% FBS, insulin (5 g/ml), hydro-
cortisone (2 g/ml), gentamicin (5 g/ml) and fungizone (2.5 g/ml).
All cells were maintained at 37°C in 5% CO2. The maintenance of the
sea urchin embryos cultures and the isolation of the sea urchin embryo
basement membranes (SU-ECM) were carried out as described pre-
viously.20,21 Phenylbutyrate was purchased from Sigma-Aldrich (St.
Louis, MO) and was dissolved in either benzene in a 1 M stock
solution or in 10 PBS in a 50 mM stock solution. Stock solutions of
phenylbutyrate were diluted to appropriate concentrations using cul-
ture media and the cells (70% confluence) were treated for 24 hr.
Invasion assay
After a 24-hr treatment with phenylbutyrate, the cells were
analyzed for their invasiveness using the sea urchin embryo base-
ment membrane invasion assay as described previously.20,21 The
media containing phenylbutyrate were aspirated and the cells were
washed with PBS. The cells were then isolated using a brief trypsin
treatment, collected by centrifugation and washed once with PBS
and centrifuged. The cells were then resuspended to a concentra-
tion of 20,000 cells/ml in the appropriate media containing either
10% FBS for the DU-145 and PC3 cells or 5% FBS for the
SUM-149 cells. The cells were then layered on top of the embryo
basement membrane invasion substrates and incubated for 4 hr at
37°C. Relative invasion was scored by phase contrast microscopic
examination. For each sample, 50-100 SU-ECM were examined
and the ratio of cancer cells located inside vs. adhering to the
outside of the SU-ECMs were calculated. The invasion percent-
ages of the control cells ranged between 12–15% and were in the
figures set as 100% relative invasiveness.
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Measurements of apoptosis and clonogenic survival
For apoptotic cell examinations, cells were treated with different
concentrations of phenylbutyrate for 48 hr and both floating and
attached cells were then collected and analyzed for percentages of
sub-G1 DNA containing cells by flow cytometry as described
previously.23 For clonogenic survival measurements, cells were
treated with different concentrations of phenylbutyrate for 24 hr
after which the cells were rinsed, trypsinized and counted. A
known number of cells were then plated in fresh media and 10
days later the cells were fixed, stained and colonies counted under
the microscope.
RESULTS
Phenylbutyrate inhibits invasiveness of metastatic prostate and
breast cancer cells
We had shown previously that phenylbutyrate attenuated the ex-
pression of caveolin-1 in prostate cancer cells.10 Because caveolin-1 is
thought to regulate integrin signaling pathways and has been shown to
correlate with the metastatic potential of prostate cancer cells14–17 we
decided to investigate the effects of phenylbutyrate treatment on the
invasiveness of metastatic prostate and breast cancer cells using the
sea urchin embryo basement membrane (SU-ECM) invasion assay.20
This invasion assay has the advantages over the matrigel invasion
assay in that it uses naturally occurring invasion substrates consisting
of a sea urchin embryo basement membranes that are very uniform
and functionally resemble human basement membranes that are in-
vaded during the metastatic stage of cancer.20 Furthermore, this assay
can predict with greater than 99% confidence the metastatic potential
of a cancer cell line.20
We used the metastatic prostate cancer cell lines PC3 and DU-145
because they have been shown to efficiently invade SU-ECM sub-
strates.21 We found that a pretreatment of the cells for 24 hr with 2
mM phenylbutyrate markedly inhibited the ability of these cells to
invade the SU-ECM (Fig. 1). We also used the metastatic breast
cancer cell line SUM-149 and found that these cells readily invaded
the SU-ECM. Similarly to the prostate cancer cell lines, when the
breast cancer cells had been pretreated with phenylbutyrate they
completely lost their ability to invade the SU-ECM (Fig. 1).
Phenylbutyrate inhibits invasiveness in a dose-dependent
manner
We next investigated the dose response of phenylbutyrate on the
inhibition of invasion of SU-ECM. We pretreated DU-145 prostate
cancer cells for 24 hr with doses of phenylbutyrate ranging from
0.1–2.0 mM before testing their invasiveness. The results show
that phenylbutyrate inhibits invasion in a dose-dependent manner
(Fig. 2). Invasiveness was reduced to 54%, 24% and 13% com-
pared to mock-treated control cells when cells had been pretreated
with 0.1 mM, 0.5 mM and 2.0 mM, respectively.
Blockage of invasion by phenylbutyrate is not readily reversible
In the clinical setting, continuous treatment of patients with
chemotherapeutic drugs is often not feasible. Consequently, the
effects of the drugs may rapidly diminish after termination of
treatment. To investigate whether the inhibitory effect of phenyl-
butyrate on the invasiveness of metastatic cancer cells is transient
or would persist even 24 hr after the drug had been removed from
the cells, we chased phenylbutyrate-treated cells with fresh media
for 24 hr before analyzing invasiveness. The results show that
incubation for 24 hr in drug-free media after 24 hr of phenylbu-
tyrate treatment did not diminish the inhibition of invasion (Fig. 3).
In fact, we observed an even greater inhibition for the chased cells
than for the cells tested directly after phenylbutyrate treatment.
Thus, the inhibitory effects of phenylbutyrate on invasion appear
to be persistent for at least 24 hr after drug removal.
Inhibition of invasion is not explained by loss of cell survival
The mechanism by which phenylbutyrate inhibited invasion was
not merely due to the toxicity of the phenylbutyrate treatment,
FIGURE 1 – Phenylbutyrate effectively inhibits the invasiveness of
metastatic prostate and breast cancer cells in the SU-ECM invasion
assay. Cells were pre-treated with 2 mM phenylbutyrate for 24 hr
before being washed, trypsinized and subjected to the SU-ECM inva-
sion assay. The data is presented as the relative percentage of cells
invading the SU-ECM and represents the average of 2–6 independent
experiments. Error bars  SEM. The actual invasion percentage of
untreated control cells were 14.5  2.1 (n  6), 13.1  1.25 (n  2)
and 12.5  0 (n  2) for DU-145, PC3 and SUM-149, respectively.
The data for the DU-145 cells was pooled from all the experiments
shown (n  6).
FIGURE 2 – Phenylbutyrate inhibits invasiveness in a dose-depen-
dent manner. DU-145 cells were pretreated with different doses of
phenylbutyrate before the cells were washed, trypsinized and subjected
to the SU-ECM invasion assay. The data is presented as the relative
percentage of cells invading the SU-ECM and represents the average
of 2–6 independent experiments. Error bars  SEM. The data for
the control and 2 mM dose is pooled from all the experiments shown
(n  6).
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because we observed that the cells that “missed” the invasion
substrates readily attached and spread out at the bottom of the
wells. To further evaluate the effect phenylbutyrate have on cell
survival we treated cells with increasing doses of phenylbutyrate
and measured either the induction of apoptosis or loss of clono-
genic survival (Fig. 4). Only modest increases in apoptosis or loss
of clonogenic survival were observed after treatments with phe-
nylbutyrate. Thus, these results suggest that the inhibitory effect of
phenylbutyrate on the invasion of the SU-ECM found in our study
can not be explained by loss of viability.
DISCUSSION
Using the sea urchin embryo basement membrane (or SU-ECM)
invasion assay, we showed that the HDAC inhibitor phenylbu-
tyrate markedly inhibited the invasiveness of metastatic prostate
and breast cancer cells. This inhibition was dose-dependent with
about 50% inhibition observed at doses as low as 100 M and
complete inhibition observed for some cancer cell lines at 2 mM.
Furthermore, the inhibition of invasiveness was found to persist for
at least 24 hr after drug removal suggesting that the inhibitory
effect of phenylbutyrate was not transient. These results are in
concordance with previous studies showing that HDAC inhibitors
can inhibit the ability of metastatic cells to invade artificial matri-
gel invasion substrates.18,19 The present study using naturally
occurring sea urchin embryo basement membranes showed a more
dramatic inhibition compared to previous studies using artificial
matrigel invasion chambers, suggesting that the potential inhibi-
tory effect of phenylbutyrate on invasiveness of cancer cells in
vivo may be even greater than previously thought.
The mechanism by which phenylbutyrate inhibits the invasive
properties of metastatic cancer cells may involve HDAC-inhibi-
tion-mediated alterations of gene expression. A number of genes
with proposed functions in the invasion process have been shown
to have altered expression after treatment with HDAC-inhibitors.
Caveolin-1, MMP-2 and urokinase have been found to be down-
regulated,10,18,24,25 whereas the MMP inhibitors TIMP-1 and
TIMP-2 are upregulated by butyrate.26 Although some apoptosis
has been observed in cancer cells after long exposures to 2 mM
phenylbutyrate,5,7,12 we do not believe that induction or commit-
ment to apoptosis is responsible for the loss of invasiveness of
these cells after 24-hr incubations with phenylbutyrate. First, phe-
nylbutyrate-treated cells appeared viable by microscopic evalua-
tion and were able to attach to and spread out on the surface in the
bottom of the wells similarly to the untreated cells. Second, cells
treated for 48 hr showed only a modest increase in the induction of
FIGURE 3 – Inhibition of invasiveness by phenylbutyrate is not
readily reversible. DU-145 cells were pretreated with 2 mM phenyl-
butyrate before the cells were washed and incubated for an additional
24 hr in drug-free media (PB  chase). The cells were then trypsinized
and subjected to the SU-ECM invasion assay. The data is presented as
the relative percentage of cells invading the sea urchin embryo sub-
strates and represents the average of 2–6 independent experiments.
Error bars  SEM. The data for the control and phenylbutyrate
(PB)-treated cells is pooled from all the experiments shown (n  6).
FIGURE 4 – Modest induction of apoptosis or loss of clonogenic
survival by phenylbutyrate. (a) DU145 prostate cancer cells were
treated with different concentrations of phenylbutyrate for 48 hr fol-
lowed by flow cytometric analysis of the percentages of sub-G1 DNA
containing cells. The bars represent the mean of 4 biological experi-
ments. Error bars  sample SD. (b) PC3 prostate cancer cells were
treated for 24 hr with different concentrations of phenylbutyrate before
known numbers of cells were seeded and allowed to grow into colo-
nies for ten days. The values represent the mean of 5 different
biological experiments done in triplicates (n  15). Error bars 
sample SD.
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apoptosis. Significant apoptosis measured as sub-G1 DNA con-
taining cells did not occur until after 72–96 hr of treatment with the
higher doses (data not shown). Third, only a modest reduction in
clonogenic survival was observed after a 24-hr treatment with
phenylbutyrate.
The findings that prolonged treatments with phenylbutyrate can
induce apoptosis directly in cancer cells5,7,12 and acts in synergy
with radiation or chemotherapy to induce apoptosis10,12 makes
phenylbutyrate very attractive as a potential anti-cancer agent. The
findings in our study that phenylbutyrate effectively inhibits inva-
siveness of metastatic cancer cells at doses that can be safely
achieved in patients1,27 points to a new exciting possibility that
phenylbutyrate may be useful as an anti-cancer agent in targeting
the invasion phase of metastatic cancers.
ACKNOWLEDGEMENTS
We would like to thank S. Ethier, University of Michigan, for
kindly providing the SUM-149 cell line and the members of the
Ljungman and Livant labs for valuable input into our study. Our
study was supported by NIH Specialized Programs of Research
Excellence in Prostate Cancer Grant to University of Michigan
(2-P50-CA69568).
REFERENCES
1. Gore SD, Carducci MA. Modifying histones to tame cancer: clinical
development of sodium phenylbutyrate and other histone deacetylase
inhibitors. Expert Opin Investig Drugs 2000;9:2923–34.
2. Marks P, Rifkind R, Richon V, Breslow R, Miller T, Kelly W. Histone
deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;
1:194–02.
3. Kruh J, Tichonicky L, Defer N. Effect of butyrate on gene expression.
In: Bider HJ, Cummings J, Soergel K. Short chain fatty acids. Dor-
drecht: Kluwer; 1994. p135–47.
4. Gore SD, Samid D, Weng LJ. Impact of the putative differentiating
agents sodium phenylbutyrate and sodium phenylacetate on prolifer-
ation, differentiation, and apoptosis of primary neoplastic myeloid
cells. Clin Cancer Res 1997;3:1755–62.
5. Carducci MA, Nelson JB, Chan-Tack KM, Ayyagari SR, Sweatt WS,
Campbell PA, Nelson WG, Simons JW. Phenylbutyrate induces ap-
optosis in human prostate cancer and is more potent than phenylace-
tate. Clin Cancer Res 1996;2:379–87.
6. Liu L, Shack S, Stetler-Stevenson WG, Hudgins WR, Samid D.
Differentiation of cultured human melanoma cells induced by the
aromatic fatty acids phenylacetate and phenylbutyrate. J Invest Der-
matol 1994;103:335–40.
7. Melchior SW, Brown LG, Figg WD, Quinn JE, Santucci RA, Brunner
J, Thuroff JW, Lange PH, Vessella RL. Effects of phenylbutyrate on
proliferation and apoptosis in human prostate cancer cells in vitro and
in vivo. Int J Oncol 1999;14:501–8.
8. Arundel CM, Glicksman AS, Leith JT. Enhancement of radiation
injury in human colon tumor cells by the maturational agent sodium
butyrate (NaB). Radiat Res 1985;104:443–8.
9. Miller AC, Whittaker T, Thibault A, Samid D. Modulation of radia-
tion response of human tumour cells by the differentiation inducers,
phenylacetate and phenylbutyrate. Int J Radiat Biol 1997;72:211–8.
10. Goh M, Chen F, Paulsen MT, Yeager AM, Dyer ES, Ljungman M.
Phenylbutyrate attenuates the expression of Bcl-X-L, DNA-PK,
caveolin-1, and VEGF in prostate cancer cells. Neoplasia 2001;3:
331–8.
11. Chung DH, Zhang FF, Chen F, McLaughlin WP, Ljungman M.
Butyrate attenuates BCLXL expression in human fibroblasts and acts
in synergy with ionizing radiation to induce apoptosis. Radiat Res
1998;149:187–94.
12. Witzig TE, Timm M, Stenson M, Svingen PA, Kaufmann SH. Induc-
tion of apoptosis in malignant B cells by phenylbutyrate or phenyl-
acetate in combination with chemotherapeutic agents. Clin Cancer
Res 2000;6:681–92.
13. Kwon HJ, Kim MS, Kim MJ, Nakajima H, Kim KW. Histone
deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer
2002;97:290–6.
14. Chapman HA, Wei Y, Simon DI, Waltz DA. Role of urokinase
receptor and caveolin in regulation of integrin signaling. Thromb
Haemost 1999;82:291–7.
15. Thompson TC. Metastasis-related genes in prostate cancer: the role of
caveolin-1. Cancer Metastasis Rev 1998;17:439–42.
16. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu
Y, Bangma CH, Kattan MW, Scardino PT, Thompson TC. Elevated
expression of caveolin is associated with prostate and breast cancer.
Clin Cancer Res 1998;4:1873–80.
17. Bangma CH, Nasu Y, Ren C, Thompson TC. Metastasis-related genes
in prostate cancer. Semin Oncol 1999;26:422–7.
18. Engelhard HH, Homer RJ, Duncan HA, Rozental J. Inhibitory effects
of phenylbutyrate on the proliferation, morphology, migration and
invasiveness of malignant glioma cells. J Neurooncol 1998;37:97–08.
19. Reynolds S, Cederberg H, Chakrabarty S. Inhibitory effect of 1-O (2
methoxy) hexadecyl glycerol and phenylbutyrate on the malignant
properties of human prostate cancer cells. Clin Exp Metastasis 2000;
18:309–12.
20. Livant DL, Linn S, Markwart S, Shuster J. Invasion of selectively
permeable sea urchin embryo basement membranes by metastatic
tumor cells, but not by their normal counterparts. Cancer Res 1995;
55:5085–93.
21. Livant DL, Brabec RK, Pienta KJ, Allen DL, Kurachi K, Markwart S,
Upadhyaya A. Anti-invasive, antitumorigenic, and antimetastatic ac-
tivities of the PHSCN sequence in prostate carcinoma. Cancer Res
2000;60:309–20.
22. Gibson AW, Burke RD. Migratory and invasive behavior of pigment
cells in normal and animalized sea urchin embryos. Exp Cell Res
1987;173:546–57.
23. Chen F, Chang D, Goh M, Klibanov SA, Ljungman M. Role of p53
in cell cycle regulation and apoptosis following exposure to protea-
some inhibitors. Cell Growth Differ 2000;11:239–46.
24. Krupitza G, Grill S, Harant H, Hulla W, Szekeres T, Huber H, Dittrich
C. Genes related to growth and invasiveness are repressed by sodium
butyrate in ovarian carcinoma cells. Br J Cancer 1996;73:433–8.
25. Kim MS, Son MW, Kim WB, In Park Y, Moon A. Apicidin, an
inhibitor of histone deacetylase, prevents H-ras-induced invasive phe-
notype. Cancer Lett 2000;157:23–30.
26. Emenaker NJ, Basson MD. Short chain fatty acids inhibit human
(SW1116) colon cancer cell invasion by reducing urokinase plasmin-
ogen activator activity and stimulating TIMP-1 and TIMP-2 activities,
rather than via MMP modulation. J Surg Res 1998;76:41–6.
27. Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y,
Donehower RC, Carducci MA. A phase I dose escalation and bio-
availability study of oral sodium phenylbutyrate in patients with
refractory solid tumor malignancies. Clin Cancer Res 2001;7:2292–
00.
499PHENYLBUTYRATE INHIBITS INVASION
